1. Academic Validation
  2. Synthesis and biological evaluation against Leishmania donovani of novel hybrid molecules containing indazole-based 2-pyrone scaffolds

Synthesis and biological evaluation against Leishmania donovani of novel hybrid molecules containing indazole-based 2-pyrone scaffolds

  • Medchemcomm. 2018 Nov 19;10(1):120-127. doi: 10.1039/c8md00475g.
M El Ghozlani 1 L Bouissane 1 M Berkani 1 S Mojahidi 1 A Allam 1 C Menendez 2 S Cojean 3 P M Loiseau 3 M Baltas 2 E M Rakib 1
Affiliations

Affiliations

  • 1 Laboratoire de Chimie Organique et Analytiques , Faculté des Sciences et Techniques , Université Sultan Moulay Slimane , B.P. 523, Béni-Mellal , Morocco . Email: [email protected].
  • 2 Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique , Université Paul Sabatier , UMR-CNRS 5068, 118 route de Narbonne , 31062 Toulouse cedex 9 , France.
  • 3 Chimiothérapie Antiparasitaire , UMR 8076 CNRS Faculté de Pharmacie , Université Paris-Saclay , Rue Jean-Baptiste Clément , F-92290 Chatenay-Malabry , France.
Abstract

A series of novel indazole-pyrone hybrids were synthesized by a one pot reaction between N-alkyl-6(5)-nitroindazoles and 2-pyrone (4-hydroxy-6-methyl-2H-pyran-2-one) using indium or stannous chloride as the reducing system in the presence of acetic acid in tetrahydrofuran. The hybrid molecules were obtained in good to excellent yields (72-92%) and characterized by NMR and single crystal X-ray diffraction. Nineteen compounds were tested in vitro against both Leishmania donovani (MHOM/ET/67/HU3, also called LV9) axenic and intramacrophage amastigotes. Among all, five compounds showed anti-leishmanial activity against intracellular L. donovani with an IC50 in the range of 2.25 to 62.56 μM. 3-(1-(3-Chloro-2-ethyl-2H-indazol-6-ylamino)ethylidene)-6-methyl-3H-pyran-2,4-dione 6f was found to be the most active compound for axenic amastigotes and intramacrophage amastigotes of L. donovani with IC50 values of 2.48 ± 1.02 μM and 2.25 ± 1.89 μM, respectively. However, the cytotoxicity of the most promising compound justifies further pharmacomodulations.

Figures